West Pharmaceutical Services Inc (WST)

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.

• 年次報告書（10-K）

  事業内容、財務実績、リスクをまとめた年次の概要。

  提出日: 2026-02-17

  書類を見る

• 四半期報告書（10-Q）

  直近3か月間の業績に関する最新情報。

  提出日: 2026-07-23

  書類を見る

• 臨時報告書（8-K）

  経営陣の交代や重要な発表など、大きな出来事に関するお知らせ。

  提出日: 2026-07-23

  書類を見る

• 4/23/2026POSITIVE
  West Pharmaceutical Lifts Annual Guidance After Strong GLP-1 Driven Growth In Q1

  West Pharmaceutical Services Inc. reported Q1 results that surpassed analyst expectations, driven by robust demand for GLP-1 drug delivery components. The company has consequently raised its full-year 2026 financial guidance, signaling strong confidence in continued growth. Furthermore, West Pharmaceutical announced a new $1 billion share repurchase program, indicating a commitment to returning capital to shareholders. This combination of exceeding current performance, improving future outlook, and enhancing shareholder value makes the stock an attractive prospect for investors.